On September 18, 2025, Humacyte, Inc. announced the publication of new preclinical data in JACC: Basic to Translational Science, a specialist journal from the Journal of the American College of Cardiology. The study evaluated the coronary tissue engineered vessel (CTEV) as a coronary artery bypass graft conduit in a non-human primate model.
The results showed that all implanted CTEVs remained patent through six months, demonstrated adaptive remodeling, and recellularized with host coronary artery cells. This suggests that the CTEV, also known as the small-diameter ATEV, may be a durable alternative CABG conduit, addressing a significant unmet clinical need where current options like saphenous vein grafts have poor long-term patency.
Humacyte plans to advance the CTEV into its first-in-human study in CABG, with an Investigational New Drug (IND) application anticipated to be filed with the FDA during the fourth quarter of 2025. This publication provides crucial scientific validation for this key pipeline program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.